Breast Carcinoma In Situ

A condition in which abnormal cells have not spread outside the duct, lobule, or nipple to other tissues of the breast. There are 3 types of breast carcinoma in situ: DUCTAL CARCINOMA IN SITU; LOBULAR CARCINOMA IN SITU; and PAGET DISEASE OF THE NIPPLE.

Also Known As:

LCIS, Lobular Carcinoma In Situ; Lobular Carcinoma In Situ

Networked: 203 relevant articles (4 outcomes, 19 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Noninfiltrating Intraductal Carcinoma (DCIS)
2.	Breast Neoplasms (Breast Cancer)
3.	Hyperplasia
4.	Neoplasms (Cancer)
5.	Carcinoma (Carcinomatosis)

Experts

1.	Schnitt, Stuart J: 4 articles (10/2022 - 10/2013)
2.	Morrow, Monica: 4 articles (07/2019 - 05/2004)
3.	Sneige, Nour: 3 articles (01/2020 - 10/2002)
4.	Lakhani, Sunil R: 3 articles (01/2018 - 05/2008)
5.	Simpson, Peter T: 3 articles (01/2018 - 05/2008)
6.	Reis-Filho, Jorge S: 3 articles (04/2015 - 04/2002)
7.	Wickerham, D Lawrence: 3 articles (05/2014 - 01/2003)
8.	Darvishian, Farbod: 2 articles (10/2022 - 12/2019)
9.	Brogi, Edi: 2 articles (05/2022 - 04/2015)
10.	King, Tari A: 2 articles (03/2022 - 04/2015)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Breast Carcinoma In Situ:

1.	Cadherins (E-Cadherin)IBA 10/01/2013 - "Our study demonstrated that florid lobular carcinoma in situ shares the cytologic features, E-cadherin loss, and the lobular genetic signature of 1q gain and 16q loss found in classic lobular carcinoma in situ. " 12/01/2022 - "Lobular carcinoma in situ (LCIS) is a non-invasive proliferation of atypical dyscohesive epithelial cells characterized by loss or functional alteration of E-cadherin-mediated cell adhesion. " 12/01/2020 - "Adjacent lobular carcinoma in situ (LCIS) was always P-cadherin-negative (0/7). " 03/01/2011 - "The tumour was immunohistochemically negative for E-cadherin and pure lobular carcinoma in situ (LCIS) was diagnosed. " 04/01/2002 - "Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast."
2.	Tamoxifen FDA LinkGeneric 01/01/2011 - "[Is low-dose tamoxifen an effective therapy for breast carcinoma in situ?]." 12/01/2001 - "The Breast Cancer Prevention Trial (P-1: BCPT) of the National Surgical Adjuvant Breast and Bowel Project (NSABP) randomized 13,388 women, > or = 35 years of age, at increased risk for breast cancer [> or = 1.66% by Gail model criteria or with a history of lobular carcinoma in situ (LCIS)] to 5 years of tamoxifen or placebo. " 05/01/2014 - "From 1992 to 1997, 13,388 women with estimated 5-year breast cancer risk greater than 1.66% or a history of lobular carcinoma in situ (87% younger than age 65; 67% postmenopausal) were randomly assigned to tamoxifen versus placebo. " 12/04/2012 - "The patient was a 44 year-old woman with a medical history of lobular carcinoma in situ, who had been on tamoxifen for 2 years, presented with abdominal pain and distention. " 01/01/2008 - "A 54-year-old perimenopausal woman on tamoxifen (20 mg/day), gravida 0, with surgically treated invasive lobular breast cancer and extensive lobular carcinoma in situ (pT2 (m) pN0 (snl) pL0 G2 pTis (LCLIS) R0 M0 Ki-67 1%, ER+, PR+, Her-2-neu-negative) was referred for evaluation of a pelvic mass. "
3.	Aurora Kinase AIBA 01/01/2020 - "Compared with conventional (nonapocrine) pleomorphic lobular carcinoma in situ (P-LCIS), aurora kinase A was expressed in a significantly greater proportion of P-LCIS (100%). "
4.	Raloxifene Hydrochloride (Evista)FDA Link 05/01/2011 - "For the Continuing Outcomes Relevant to Evista (CORE) study population (n = 3,991; excluding women ≥86 y of age or with a history of ductal carcinoma in situ or lobular carcinoma in situ), the prevalence of risk factors to the overall IBC risk was calculated. " 01/01/2003 - "In the Study of Tamoxifen and Raloxifene trial, eligible women are at least 35 years of age and postmenopausal, with either lobular carcinoma in situ or a 5-year risk of invasive breast cancer of at least 1.67%. " 01/27/2009 - "Favourable results, that is cost saving or cost-effective, are found by both tamoxifen and raloxifene for the introduction of chemoprevention among extremely high-risk women such as having a history of atypical hyperplasia, a history of lobular carcinoma in situ or a 5-year predicted breast cancer risk of > or =5.01% starting at younger age, whereas unfavourable results, that is 'cost more and gain less' or cost-ineffective, are found for women with a 5-year predicted breast cancer risk of < or =5.00%. "
5.	Oral ContraceptivesIBA 11/01/2006 - "Our study assesses the impact of oral contraceptive use on breast carcinoma in-situ (BCIS) risk. " 11/01/2007 - "Oral contraceptive use and risk of breast carcinoma in situ." 11/01/2006 - "Oral contraceptive use and risk of breast carcinoma in situ (United States)." 09/01/2003 - "To define the role of oral contraceptive use in the development of breast carcinoma in situ. " 09/01/2003 - "Oral contraceptives and the risk of ductal breast carcinoma in situ."
6.	Indicators and Reagents (Reagents)IBA 04/01/2015 - "Lobular carcinoma in situ (LCIS) is both a risk indicator and non-obligate precursor of invasive lobular carcinoma (ILC). " 02/01/2008 - "Lobular carcinoma in situ (LCIS) of the breast is generally considered an indicator for a bilaterally increased risk of invasive breast cancer (IBC). " 11/01/2006 - "In this study, we used microarray comparative genomic hybridization (CGH) to investigate genetic changes in atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS), as the presence of these lobular neoplastic lesions is an indicator of risk in the development of invasive breast cancer. "
7.	ParaffinIBA 01/01/2000 - "Most studies of p53 in breast carcinoma in situ are immunohistochemical studies of p53 staining in paraffin-embedded tissue sections. " 04/01/2015 - "We analyzed HER2 mutation and pathologic factors on 73 formalin-fixed, paraffin-embedded samples, including 21 pleomorphic invasive lobular carcinoma (p-ILC) cases, 3 pleomorphic lobular carcinoma in situ (p-LCIS) cases, and 49 classic invasive lobular carcinoma (c-ILC) cases. "
8.	Technetium Tc 99m Sestamibi (Cardiolite)FDA LinkGeneric 01/01/2005 - "The aim of the study was to retrospectively define specific features of the technetium-99m pentavalent dimercaptosuccinic acid (99mTc-(V)DMSA) and technetium-99m 2-methoxy isobutyl isonitrile (99mTc-Sestamibi [99mTc-MIBI]) distribution in ductal breast carcinoma in situ and lobular breast carcinoma in situ (DCIS/LCIS), in relation to mammographic, histological and immunohistochemical parameters. "
9.	Succimer (Dimercaptosuccinic Acid)FDA Link 01/01/2005 - "The aim of the study was to retrospectively define specific features of the technetium-99m pentavalent dimercaptosuccinic acid (99mTc-(V)DMSA) and technetium-99m 2-methoxy isobutyl isonitrile (99mTc-Sestamibi [99mTc-MIBI]) distribution in ductal breast carcinoma in situ and lobular breast carcinoma in situ (DCIS/LCIS), in relation to mammographic, histological and immunohistochemical parameters. "
10.	Contraceptive Agents (Contraceptives)IBA 01/01/2017 - "We evaluated the associations of these reproductive factors with TNBC, in 2658 patients with breast cancer (including 554 with TNBC) and 2448 controls aged 20-64 years, who participated in one of the three population-based case-control studies: the Women's Contraceptive and Reproductive Experiences Study, the Women's Breast Carcinoma in situ Study, or the Women's Learning the Influence of Family and Environment Study. "

Therapies and Procedures

1.	Chemoprevention 12/01/2023 - "We conducted a retrospective cohort study among women with atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS), an important target population for chemoprevention. " 03/01/2021 - "For example, the Breast Cancer Risk Assessment Tool, which identifies women who would benefit from chemoprevention, is readily accessible and user-friendly but cannot be used in women under 35 years of age or those with prior breast cancer or lobular carcinoma in situ. " 07/01/2019 - "Women seen in a high-risk clinic from October 2014 to June 2017 considered eligible for chemoprevention (history of lobular carcinoma in situ, atypia, family history of breast/ovarian cancer, genetic mutation, or history of chest wall radiation) were retrospectively identified. " 09/01/2022 - "High-risk breast lesions such as atypical hyperplasia and lobular carcinoma in situ are also frequently encountered, and while benign, they do increase the future risk of breast cancer and patients should be offered intensive surveillance and chemoprevention." 02/01/2015 - "The likelihood of accepting chemoprevention was associated with lifetime breast cancer risk and was higher for women with specific high risk conditions (lobular carcinoma in situ and atypical ductal hyperplasia). "
2.	Radiotherapy 06/28/2017 - "For Detroit, patients under stage 0, grade undetermined, histology lobular carcinoma in situ, and age between 26-50 were found more likely to receive breast-conservation surgery without radiotherapy. " 04/01/1990 - "The role of simple excision with or without radiotherapy in breast carcinoma in situ remains to be determined." 02/01/2005 - "Breast-conserving surgery and radiotherapy: a possible treatment for lobular carcinoma in situ?" 01/15/1998 - "The purpose of this study is to assess the long-term outcome of breast cancer patients with a component of lobular carcinoma in situ (LCIS) treated with conservative surgery and radiation therapy. " 03/01/2000 - "The relation between the presence and extent of lobular carcinoma in situ and the risk of local recurrence for patients with infiltrating carcinoma of the breast treated with conservative surgery and radiation therapy."
3.	Mastectomy (Mammectomy) 01/01/2020 - "Extensive Florid Lobular carcinoma in situ presenting as a large breast mass requiring a mastectomy." 12/01/2015 - "Rates of upstaging after local excision, positive or close margins, mastectomy, and recurrence associated with pure pleomorphic lobular carcinoma in situ were examined. " 03/20/2009 - "Young patient age, white race, recent year of diagnosis, and the presence of lobular carcinoma in situ were significantly associated with higher CPM rates among all surgically treated patients and all patients undergoing mastectomy. " 02/01/2008 - "In a retrospective study, we describe the location and incidence of PD and other pale cells in the nipple epidermis, in 288 mastectomy specimens from women operated on for breast carcinoma, in situ or infiltrating, selected consecutively from our histopathologic files. " 02/01/2005 - "Lobular carcinoma in situ (LCIS) is generally treated by conservative surgery alone and less often by mastectomy. "
4.	Therapeutics 01/01/2020 - "Disparities in Risk Reduction Therapy Recommendations for Young Women With Lobular Carcinoma In-Situ." 02/01/2019 - "Trends in lobular carcinoma in situ management: endocrine therapy use in California and New Jersey." 08/01/2008 - "Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy." 03/01/1994 - "Lobular carcinoma in situ: observation without surgery as an appropriate therapy." 10/01/1991 - "Breast carcinoma in situ in 167 women--incidence, mode of presentation, therapy and follow-up."
5.	Segmental Mastectomy (Lumpectomy) 10/01/2023 - "Does Non-Classic Lobular Carcinoma In Situ at the Lumpectomy Margin Increase Local Recurrence?" 03/01/2019 - "Breast-conserving surgery for pure non-classic lobular carcinoma in situ: A single institution's experience." 06/01/2016 - "To evaluate imaging features of pure lobular carcinoma in situ (LCIS) on magnetic resonance imaging (MRI) in patients who underwent immediate re-excision after lumpectomy. " 06/01/2016 - "Features of Pure Lobular Carcinoma In Situ on Magnetic Resonance Imaging Associated with Immediate Re-Excision after Lumpectomy." 08/01/2014 - "For women >40 years old, the presence of LVSI (hazard ratio [HR] 2.5) and the presence of lobular carcinoma in situ in the lumpectomy specimen (HR 2.3) were the only 2 risk factors. "